ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
40 Hz vibrotactile stimulation ameliorates amyloid pathology and cognitive deficits in 5xFAD mice and is associated with alterations in Piezo1, ERK, and GSK-3β/p65 signaling.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
40 Hz vibrotactile stimulation (VTS) is an emerging non-invasive therapy for Alzheimer's disease (AD), yet its specific mechanisms regarding amyloid-beta (Aβ) metabolism remain unclear. Six-month-old 5xFAD mice received daily 40 Hz VTS for four weeks. We assessed cognitive function, Aβ pathology, and underlying molecular pathways. VTS improved spatial learning and recognition memory, whereas no significant improvement was observed in short-term spatial working memory. VTS reduced hippocampal Aβ plaque burden and cortical soluble Aβ40 and Aβ42 levels, accompanied by decreased expression of APP, BACE1, and PS1 and increased expression of ADAM10 and IDE. It further attenuated neuroinflammation, oxidative stress and produced changes in cholinergic and synaptic plasticity-associated proteins. VTS increased hippocampal Piezo1 expression and ERK phosphorylation, increased inhibitory phosphorylation of GSK-3β at Ser9, decreased p65 phosphorylation, and reduced tau phosphorylation. 40 Hz VTS ameliorates several cognitive and neuropathological features of AD in 5xFAD mice. These improvements are associated with the modulation of Piezo1, ERK, and GSK-3β/p65 signaling pathways, highlighting its potential as a promising non-invasive AD therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.